Search Seeds - Search Cannabis Medical Articles - Seach eBooks

ENCEPHALOMYELITIS/ EAE & Cannabis Studies Completed

Overview

Symptoms represent an acquired complex and debilitating disorder that is characterised by profound fatigue and cognitive problems which do not improve with bed rest and becomes worse with physical and mental exertion

Encephalomyelitis is a general term for inflammation of the brain and spinal cord, describing a number of disorders:


  • Acute disseminated encephalomyelitis or postinfectious encephalomyelitis, a demyelinating disease of the brain and spinal cord, possibly triggered by viral infection;
  • Encephalomyelitis disseminata, a synonym for multiple sclerosis;
  • Equine encephalomyelitis, a potentially fatal mosquito-borne viral disease that infects horses and humans;
  • Myalgic encephalomyelitis, a syndrome involving inflammation of the central nervous system with symptoms of muscle pain and fatigue; the term has sometimes been used interchangeably with chronic fatigue syndrome, though there is still controversy over the distinction.
  • Experimental autoimmune encephalomyelitis (EAE), an animal model of brain inflammation.

Science and Research

2012 - Study ~ Cannabinoid receptor-2-selective agonists improve recovery in experimental autoimmune encephalomyelitis
2012 - Study ~ Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB(1) receptor-mediated anti-inflammatory effects.
2012 - Study ~ Cannabinoid receptor 2 agonists inhibit migration of activated dendritic cells via modulation of MMP-9

2011 - Study ~ Administration of 2-arachidonoylglycerol ameliorates both acute and chronic Experimental Autoimmune Encephalomyelitis
2009 - Study ~ Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke
2008 - Study ~ The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.
2008 - Study ~ CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies
2008 - Study ~ Cannabinoids in the management of spasticity associated with multiple sclerosis

2007 - Study - CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies

2007 - Study - The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis

2007 - Study ~ Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors
2007 - Study ~ A Cannabinoid CB2 receptor agonist attenuates experimental autoimmune encephalomyelitis (EAE) and reduces MOG-specific T cell proliferation

2006 - Study ~ Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection
2005 - Study ~ Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation.
2003 - Study ~ Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+) WIN55,212
1997 - Study ~ Suppression of experimental autoimmune encephalomyelitis by cannabinoids.

Top Home

Oops! This site has expired.

If you are the site owner, please renew your premium subscription or contact support.